Navigation Links
Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control and Reducing Diabetic Cardiovascular Complications

CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC, in conjunction with its commercialization partner S2 Therapeutics, Inc., reported today the results of its Phase IIIb clinical trial supporting the overall and cardiovascular safety of Cycloset(TM) (A quick release formulation of bromocriptine mesylate) in subjects with type 2 diabetes. The study, which highlighted a significant reduction in the risk of diabetic cardiovascular complications in subjects treated with Cycloset(TM) compared to placebo, also confirmed the drug's ability to improve glycemic control in subjects failing metformin plus sulfonylurea therapy.

The data were presented by the principle investigator, J. Michael Gaziano, MD, MPH, Cardiologist at Brigham and Women's Hospital and Veteran Affairs Boston Healthcare System, Boston, MA as a late-breaking poster at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. (June 22-26, 2007).

Cycloset(TM) is being investigated as a once-daily, timed oral therapy for type 2 diabetes that acts upon the central nervous system (CNS) to impact peripheral metabolism. The Phase IIIb trial was conducted in response to an approvable letter from the FDA requesting additional data on Cycloset(TM)'s cardiovascular safety.

The double-blind, multi-center trial's 3,070 participants included subjects with type 2 diabetes between the ages of 30 and 80 with HbA1c less than or equal to 10.0 and BMI less than or equal to 43. Participants randomized into the study were all on a treatment regimen for their diabetes, which could include either diet alone, up to two oral hypoglycemic agents, insulin alone, or insulin with no more than one oral agent. Participants were randomized in a 2:1 ratio to Cycloset(TM) (2,054 subjects; titrated from 1.6 mg/day to a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... even minor orthopaedic trauma can lead to medical problems ... Feb. 25 Pregnant women who experience orthopaedic trauma ... prenatal complications if they receive care at a medical ... injuries, according to a study presented today at the ...
... New research offers hope, propels treatment for common orthopaedic ... and the Orthopaedic Research and Education Foundation (OREF) presented ... gap between basic research and clinical medicine, at the ... Orthopaedic Surgeons (AAOS) ( http://www.aaos.org/ ) . ...
Cached Medicine Technology:Orthopaedic Injury: High Risk to Pregnant Women 2Orthopaedic Injury: High Risk to Pregnant Women 3Applying Clinical Findings to the Practice of Medicine 2Applying Clinical Findings to the Practice of Medicine 3Applying Clinical Findings to the Practice of Medicine 4Applying Clinical Findings to the Practice of Medicine 5
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... Addition of intravenous magnesium sulfate to standard emergency ... rather than enhance the effectiveness of treatment.// Dr. ... College of Medicine in the Bronx, New York, ... be helpful in the treatment of migraine headache ...
... in animal products raises the risk of breast cancer, ... suggested a link between a high fat diet, rich ... based in Chicago, USA, reveals that dietary differences might ... high where the proportion of daily calories from animal ...
... killer, accounting for one in four deaths, more than ... that the diversity of lung disease has yet to ... deal only in one disorder, chest physicians look after ... asthma, pneumonia, cystic fibrosis and sleep apnoea. There are ...
... complications in ovarian cancer. A gene implicated in inherited ovarian ... Up to 10 per cent of cases of ovarian cancer ... these cases, the woman usually has a strong family history ... developing, although it's not yet known in detail how it ...
... year worldwide if more people at high risk of having ... An analysis of nearly 300 clinical trials of aspirin and ... that aspirin reduces heart attacks and strokes in susceptible patients. ... from aspirin and anti-platelet therapy receive it. ,“This ...
... at Hopkins University, they have found a way to use ... system, surpassing an obstacle to certain forms of gene ... body's immune response to developing cancer vaccines to reducing the ... core of the blood system.// They can give rise to ...
Cached Medicine News:Health News:A new study surpasses Gene Therapy Hurdle 2
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... cardiac surgery patients require progressive solutions that ... return to everyday life. Since the ... have been able to provide nearly 400,000 ... care:, Faster ambulation , Shorter hospital ...
... CF-60DSi is an all-digital Fundus camera system that ... efficient workflow. The Canon CF-60DSi ... EOS-1Ds series SLR digital camera features a "full ... resolution and the new ICG unit, which features ...
... Intacs prescription inserts are an ophthalmologic medical ... of myopia from -1.00 to -3.00 diopters.* ... of the patient's central optical zone, the ... cornea. Intacs inserts is composed of two ...
Medicine Products: